Drugs / Vebicorvir
Vebicorvir
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04637139 | Dec 2020 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02908191 | Nov 2016 → Mar 2018 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03109730 | Jun 2017 → Mar 2018 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05238844 | Apr → May 2022 | chronic hepatitis B virus infection | Antios Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT04781647 | Feb 2021 → Dec 2022 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04454567 | Nov 2020 → Apr 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT03577171 | Jun 2018 → Jun 2019 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT03576066 | Jun 2018 → Jul 2019 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vebicorvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238844 ↗ |
| Known as | ABI-H0731 | “Vebicorvir (formerly ABI-H0731) is an orally administered, potent and selective small molecule inhibitor of the HBV core protein” NCT05238844 ↗ |
| Known as | VBR | “Vebicorvir (VBR)” NCT04637139 ↗ |
| Action | Inhibit | “an investigational inhibitor of the HBV core protein” PMID 31711752 ↗ Nov 2019 |
| Modality | Small molecule | “small molecule inhibitor” NCT05238844 ↗ |
| Route | Oral | “single oral doses of ABI-H0731 (100, 300, 600, or 1000 mg)” PMID 31711752 ↗ Nov 2019 |